Peptide guide

Ipamorelin: what it is and what the research actually shows

A growth hormone releasing peptide with exactly one published human trial. It was a small surgery study that found no benefit over placebo.

Byline: Mark Sommers, editor. Sources checked 08-26-2026. Every claim below links to its PubMed record or FDA page.

Quick facts

What is in it
  • One synthetic peptide made in a lab. It is a short chain of five amino acids, built to switch on the ghrelin receptor and trigger the pituitary gland to release growth hormone.

One molecule, not a blend. Ipamorelin sold pre-mixed with other peptides, most often CJC-1295, is a different product than anything tested in the trials below, and none of those combinations have been studied in people.

Studied for
The only human trial tested whether ipamorelin could speed up the return of normal bowel function after abdominal surgery, a problem called postoperative ileus. It did not show a benefit. No human trial has tested ipamorelin for the things it is most often sold for now, including muscle gain, fat loss, sleep, or general anti-aging use. Animal studies have looked at bone growth, body fat, insulin release, and gastric motility.
Human evidence, part by part
IpamorelinLimited2 human studies found
Approved by the FDA?
Not approved as a drug for any use. FDA places ipamorelin acetate in Category 2 of its bulk drug substance review, meaning it may present significant safety risks and cannot lawfully be used in compounding. See where it stands.

Benefits

  • Evidence Increased bone mineral content in rats over 12 weeks, an effect similar in size to growth hormone itself. PMID 10828840
  • Evidence Protected calf muscle strength and increased new bone formation in rats also given a muscle-weakening steroid. PMID 11735244
  • Evidence Triggered a burst of growth hormone release within an hour, in a 40-person healthy-volunteer dosing study. PMID 10496658
  • Evidence Released growth hormone in rat, pig and cell studies without raising cortisol or ACTH, unlike related compounds. PMID 9849822
  • Suggested Discussed for muscle gain, fat loss, sleep and anti-aging, though no trial has tested any of those uses.
  • Suggested Promoted as a gentler growth-hormone secretagogue based on its selectivity in animal and cell studies.
  • Suggested Discussed by online clinician commentary as a classic muscle-and-recovery peptide with a cleaner side-effect reputation.

Evidence items link to the study behind them. Suggested items are claims in circulation, not results.

Reported side effects

  • The only trial testing a clinical benefit, bowel recovery after surgery, found no significant improvement over placebo. PMID 25331030
  • FDA's safety review cites that same trial as reporting serious adverse events including a death, not visible in its published abstract.
  • Overall side-effect rates were similar to placebo in the one published human trial. PMID 25331030
  • Mice given ipamorelin gained more body fat, the opposite of what most buyers hope for. PMID 11162489
  • FDA places ipamorelin in Category 2, for compounded substances that may pose significant safety risks.

Safety, before anything else

Ipamorelin is not an approved medicine, and FDA has flagged it as a compounding safety risk. FDA places it in Category 2 of its bulk drug substance review, the category for substances that may present significant safety risks, and states it cannot lawfully be used in compounded drugs. The human research behind it is thin: one small trial that found no benefit for the one thing it was tested on, and one healthy volunteer dosing study that measured blood hormone levels only. FDA's own safety review cites that same trial as reporting a death among its serious adverse events, a detail not visible in the published abstract. Read the full record below before assuming any of the marketing claims made for this compound have been tested.

Ipamorelin

  • In the one published human trial, the overall rate of any treatment emergent adverse event was 87.5% in the ipamorelin group against 94.8% in the placebo group, so ipamorelin was not associated with more side effects than placebo by this measure. The published abstract does not list individual adverse events or describe any deaths. PMID 25331030
  • ClinicalTrials.gov record NCT00672074 for that same trial, checked 08-26-2026, has never posted results. The per arm breakdown of adverse events, including whether any death occurred during the study, is not publicly available on the registry.
  • FDA's Category 2 compounding safety review, current as of 04/22/2026 and checked 08-26-2026, states that a study published in the literature reported serious adverse events, including a death, when ipamorelin was given intravenously to improve gastric motility, and links that statement directly to PMID 25331030, the same trial above. That detail does not appear in the paper's public abstract, so it could not be independently verified beyond FDA's own characterization of the full paper.
  • A second, larger trial, ClinicalTrials.gov NCT01280344, enrolled 320 people to test intravenous ipamorelin against placebo for the same recovery of gastrointestinal function after bowel surgery. It ran from 2011 to 2014, is listed as completed, and has no posted results and no matching publication in PubMed. Whatever safety or efficacy data it produced has never been made public.

We do not publish amounts or schedules of our own, on any page. The clinician commentary lower on this page quotes amounts that named clinicians state on camera, labeled and linked to the source video. Those are their words, not our guidance. Why we draw that line.

How to read the grades

Each study gets a tag. Cells in a dish means it never touched a living animal. Animals means mice or rats, usually. Small human study means a handful of people with no comparison group. Human trial means people were randomly split into treated and untreated groups, which is the only kind that can show an effect is real. Review and Systematic review sum up other studies. The full rule is on How we check.

Ipamorelin

A five amino acid peptide that binds the ghrelin receptor, also called the growth hormone secretagogue receptor, and tells the pituitary gland to release a pulse of growth hormone. It was developed in the 1990s by Novo Nordisk, which reported in animal and cell studies that it triggers growth hormone release about as strongly as older experimental compounds in the same family, but without raising cortisol or ACTH, the stress hormones that some related compounds do raise. That selectivity is the entire basis of ipamorelin's reputation. The only condition ever tested in a human trial is postoperative ileus, slow return of bowel function after abdominal surgery, and that trial found no significant benefit. Everything else people buy ipamorelin for today, muscle gain, fat loss, better sleep, slower aging, rests on the mechanism and on animal data, not on any human trial of those outcomes.

Human evidence: Limited. 2 human studies found in our search.

What has been studied

Who or what was studiedWhat was found, and the catchSource
Human trial
n = 114 people
In adults recovering from small or large bowel resection, people getting intravenous ipamorelin reached tolerance of a solid meal in a median of about 25 hours, against about 33 hours on placebo, but the difference was not statistically significant. None of the secondary efficacy measures showed a clear benefit either. One hundred seventeen patients were enrolled, and 114 made up the safety and modified intent to treat populations.
Limit: This is the only published human trial that ever tested whether ipamorelin does anything. It was designed and described by its own authors as a small proof of concept study, not a confirmatory one, and it enrolled a broad mix of surgical patients rather than one specific procedure. Its own conclusion was that there was no significant difference from placebo. A larger follow up trial was run afterward and has never been published, see the note below.
Beck 2014
PMID 25331030
Small human study
n = 40 people
In healthy young men given a single intravenous infusion at one of five escalating dose levels, eight men per level, ipamorelin cleared from the blood within about two hours and triggered a single burst of growth hormone release that peaked within an hour, with the size of that hormone response leveling off at the higher doses tested.
Limit: Forty healthy men, one dose each, no placebo group, and no patients. The only thing measured was blood levels of the drug and of growth hormone. It shows ipamorelin does what it was designed to do to growth hormone in the blood, not that this changes anything a person would feel or benefit from.
Gobburu 1999
PMID 10496658
Animals
In rat pituitary cells, anesthetized rats, and pigs, ipamorelin released growth hormone about as strongly as an older experimental compound, GHRP-6. Unlike GHRP-6 or GHRP-2, ipamorelin did not raise cortisol or ACTH even at doses far above what was needed for growth hormone release, and it did not change levels of other pituitary hormones. This selectivity is the finding the compound is best known for.
Limit: No human data at all. This is a laboratory and animal pharmacology paper from the company that invented the compound, written to describe why they thought it was a promising drug candidate, not a demonstration that it helps with any condition.
Raun 1998
PMID 9849822
Animals
In rats that had undergone bowel surgery, repeated intravenous ipamorelin over two days increased cumulative stool output, food intake, and weight gain compared with vehicle. A single dose sped up the time to the first bowel movement but did not change the other measures.
Limit: An animal surgery model, not real patients, and funded by the company developing the drug for this exact use. This is the preclinical rationale that led directly to the human ileus trial, which then found no significant benefit.
Venkova 2009
PMID 19289567
Animals
In rats with surgically delayed stomach emptying, a single intravenous dose of ipamorelin sped stomach emptying back toward the level of animals that had no surgery, and it reversed the loss of contraction strength seen in isolated stomach muscle tissue taken from operated animals.
Limit: Animal and isolated tissue data only, funded by and co-authored with the company developing the drug for postoperative ileus. It supports a mechanism that the one human trial of the same condition then failed to confirm.
Greenwood-Van Meerveld 2012
PMID 27186127
Animals
Twelve weeks of continuous ipamorelin in adult female rats increased bone mineral content measured by DXA scan and by CT scan, an effect similar in size to giving growth hormone itself. The increase tracked the overall increase in bone size and body weight rather than making the bone denser for its size.
Limit: Small groups of seven or eight rats per arm, adult rats rather than a model of any bone disease, and no comparison to any treatment used in human osteoporosis. Whether this translates into any clinical bone benefit in people has never been tested.
Svensson 2000
PMID 10828840
Animals
In rats given a steroid drug known to weaken muscle and bone, adding ipamorelin alongside the steroid for three months prevented the drop in calf muscle strength and increased the rate of new bone formation compared with the steroid given alone.
Limit: Rats only, and a specific steroid injury model, not an osteoporosis or muscle wasting trial in people. No human study has tested whether ipamorelin protects against steroid side effects.
Andersen 2001
PMID 11735244
Animals
Pancreas tissue taken from normal rats and from rats made diabetic with a toxin released more insulin when exposed to ipamorelin in a dish, and blocking calcium channels or certain adrenaline receptors reduced that effect, pointing to a specific signaling pathway.
Limit: Isolated tissue fragments in a dish, not a living animal or person, and a toxin induced rat model that is not the same as type 1 or type 2 diabetes in people. Nobody has shown this insulin effect happens in a living body, animal or human.
Adeghate 2004
PMID 15665799
Animals
Twice daily ipamorelin injections in mice increased body fat and fat pad weight over several weeks in both normal mice and mice bred to lack growth hormone, and it raised the appetite hormone leptin and food intake. The authors concluded that growth hormone secretagogues can increase body fat through a route that does not depend on growth hormone itself.
Limit: Mice, not people, and the effect measured was more body fat, not less, which is the opposite of what most people taking a growth hormone secretagogue are hoping for. This complicates the simple story that ipamorelin should improve body composition.
Lall 2001
PMID 11162489
Review
A 2026 narrative review written for sports medicine physicians groups ipamorelin with ten other unapproved peptides sold direct to patients. It notes that animal data on tissue repair and metabolism look promising for several of these compounds, but that rigorous human safety data are scarce across the group, and that there is real potential for harm.
Limit: A narrative review, not new data, covering eleven different peptides at once, so ipamorelin gets only a few sentences rather than a dedicated assessment. It reflects two authors' reading of the existing literature.
Mendias 2026
PMID 41966639
Review
A 2026 critical review of peptide use in sport and bodybuilding names ipamorelin among the growth hormone secretagogues used at combinations and frequencies well outside anything ever tested in a trial. It flags cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric symptoms as emerging safety concerns for this category of drugs, while noting that how many people are actually using them this way is unknown.
Limit: A review of the field as a whole, not a study of ipamorelin specifically. The safety concerns raised are general to the drug class and to unsupervised, self-directed use, not findings tied to a specific ipamorelin trial or reported case.
Coutinho 2026
PMID 41880199

Safety signals in the studies

  • In the one published human trial, the overall rate of any treatment emergent adverse event was 87.5% in the ipamorelin group against 94.8% in the placebo group, so ipamorelin was not associated with more side effects than placebo by this measure. The published abstract does not list individual adverse events or describe any deaths. PMID 25331030
  • ClinicalTrials.gov record NCT00672074 for that same trial, checked 08-26-2026, has never posted results. The per arm breakdown of adverse events, including whether any death occurred during the study, is not publicly available on the registry.
  • FDA's Category 2 compounding safety review, current as of 04/22/2026 and checked 08-26-2026, states that a study published in the literature reported serious adverse events, including a death, when ipamorelin was given intravenously to improve gastric motility, and links that statement directly to PMID 25331030, the same trial above. That detail does not appear in the paper's public abstract, so it could not be independently verified beyond FDA's own characterization of the full paper.
  • A second, larger trial, ClinicalTrials.gov NCT01280344, enrolled 320 people to test intravenous ipamorelin against placebo for the same recovery of gastrointestinal function after bowel surgery. It ran from 2011 to 2014, is listed as completed, and has no posted results and no matching publication in PubMed. Whatever safety or efficacy data it produced has never been made public.

Where it stands with regulators

  • FDA page listing bulk drug substances that may present significant safety risks, content current as of 04/22/2026, checked 08-26-2026. Ipamorelin acetate is in Category 2 under the 503B interim policy, added September 29, 2023. Quoting FDA directly: compounded drugs containing it 'may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities,' and 'a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.' The page links that statement directly to the same postoperative ileus trial (PMID 25331030) listed under components below. FDA adds that it 'has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration' and 'lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.' Source
  • Drugs@FDA query, checked 08-26-2026, returned NOT_FOUND. No approved ipamorelin drug product exists and no application is on record. Source
  • FDA 503A bulk drug substances page, content current as of 05/14/2026, checked 08-26-2026. Ipamorelin does not appear on this list of substances that may be used in compounding under section 503A. Source
  • FDA 503B bulk drug substances page, content current as of 01/07/2025, checked 08-26-2026. Ipamorelin does not appear on this list either, consistent with its placement in the separate Category 2 safety risk list rather than an approved compounding list. Source

What is missing

The human evidence for ipamorelin is close to the smallest possible: two published studies and roughly 154 people total, one of them a healthy volunteer dosing study that never tested for any benefit at all. The one trial that did test for a benefit, in postoperative ileus, found none. A larger, 320 person confirmatory trial for the same condition was completed in 2014 and has never been published or had results posted, so the largest human dataset on ipamorelin that exists is not public. No human trial has ever tested the uses ipamorelin is most commonly sold for now, including muscle gain, fat loss, sleep, or anti-aging. FDA's safety review states that a death occurred as a serious adverse event in the one published trial, but that detail is not visible in the paper's own abstract, leaving a real gap between what FDA says the literature shows and what a reader can verify directly.

Clinician commentary (YouTube)

This is commentary, not evidence. 4 clinicians with large audiences discuss this on camera. Each video below is summarized in our words and linked so you can watch the source yourself. Any amounts mentioned are what the named clinician says on camera, not PeptideGauge guidance. The graded studies above remain the record of what is known. How this layer works.

Dr. Alex Tatem

In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses Ipamorelin. What he says, in short:

  • He classifies ipamorelin as a growth hormone secretagogue acting on the ghrelin receptor, injectable unlike oral MK-677, that gained popularity after growth hormone access was restricted by a 1993 law change.
  • He recalls a study using it for gut healing after abdominal surgery that came back equivocal, after which it was abandoned as a drug candidate, while noting anecdotal reports that it raises IGF-1 somewhat.
  • He says because real growth hormone is now easier and cheaper to obtain, it's hard to find a strong case for ipamorelin, giving it a D tier ranking.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

Dr. Ashley Froese

In “Dr. Explains Peptide Stacks Used for Muscle Growth”, Dr. Ashley Froese discusses Ipamorelin. What she says, in short:

  • She uses a DJ analogy, GHRH peptides wake the pituitary DJ up, while ipamorelin acts like a hype man that tells the DJ to turn up the volume, increasing the amplitude of growth hormone pulses.
  • She says ipamorelin quiets somatostatin to clean up the signal and can boost growth hormone release without raising cortisol or prolactin the way some other growth hormone releasing peptides like GHRP-2, GHRP-6, and hexarelin do.
  • She calls it the cleaner amplifier and says this is why it is commonly stacked with CJC-1295 or tesamorelin, combining pulse frequency with amplitude for a synergistic effect.
  • She says ipamorelin, like most growth hormone releasing peptides, has a lot of human data behind it.
  • She warns that pushing growth hormone pathways too hard carries risk, and says anyone with an active cancer or tumor, or a strong predisposition to one, should not stimulate this pathway.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Dr. Reviews Growth Hormone vs. Peptides - Which is Better?”, Dr. Ashley Froese discusses Ipamorelin. What she says, in short:

  • She lists it among the ghrelin mimetic and growth hormone releasing hormone peptides, alongside sermorelin, tesamorelin, CJC-1295, hexarelin, GHRP-2, and GHRP-6, that amplify the body's own growth hormone signaling rather than replacing growth hormone outright.
  • She says unlike HGH, these peptides work through the body's existing release system and do not shut down natural growth hormone production.
  • She says peptides in this class create a milder, more pulsatile growth hormone release, so side effects tend to be lighter, things like flushing or extra hunger, compared to HGH.
  • She says these peptides are usually taken before bed a few nights a week to amplify the body's biggest natural growth hormone pulse during early deep sleep.
  • She says they should be cycled with days off, warning that using them every single night without breaks can lead to receptor desensitization at the pituitary.
  • She says peptides in this class have a natural ceiling because the pituitary can only release so much growth hormone at once, unlike HGH, which has no ceiling, and she frames them overall as a safer lifestyle option that works with the body's biology rather than replacing it.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

2 more videos where Dr. Ashley Froese covers Ipamorelin

In “Real Dr Explains CJC-1295 + Ipamorelin - The CLASSIC Peptide Stack”, Dr. Ashley Froese discusses Ipamorelin. What she says, in short:

  • She describes Ipamorelin as a ghrelin receptor agonist that mimics the hunger hormone, tricking the brain into a fasted state that triggers pituitary growth hormone release, giving fat-burning benefits without the hunger.
  • She says Ipamorelin selectively hits the GHSR1a receptor on the pituitary, unlike other ghrelin mimetics such as hexarelin, GHRP-2, GHRP-6, and MK-677, which are less selective and can cause more hunger, cortisol, and prolactin release, which is why she says Ipamorelin became the favored option.
  • She says Ipamorelin also tells somatostatin, the hormone that blocks growth hormone release, to back off, making growth hormone release more potent, likening it to disabling the alarm on a garage door while CJC 1295 knocks at the front door.
  • She cites a human phase two trial in about 100 people after bowel resection surgery where Ipamorelin helped the gut wake up faster after surgery, with no real safety concerns found.
  • She says studies pairing GHRH-type peptides with Ipamorelin showed the growth hormone effect was dramatically amplified rather than just additive, and that people kept their natural hormone rhythms, especially during sleep, though she notes the studies were small and short.
  • She lists side effects seen with either peptide: injection site irritation or redness, water retention, tingling in the hands, and, rarely, hives, which she says should mean stopping the peptide right away.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Muscle Builder or More? Dr Reviews Ipamorelin”, Dr. Ashley Froese discusses Ipamorelin. What she says, in short:

  • She says ipamorelin signals the pituitary to release growth hormone by mimicking ghrelin, unlike GHRH based peptides such as sermorelin, CJC-1295, and tesamorelin.
  • She cites human studies showing ipamorelin produces a growth hormone pulse that typically peaks around 40 minutes after dosing and was generally well tolerated.
  • She says a 21 day repeat dosing study found the pituitary did not become desensitized to ipamorelin, unlike GHRH peptides whose receptors can down regulate with repeated daily use.
  • She says the most commonly reported real world effects are better sleep, improved recovery, and gradual body composition change over a couple of months, not dramatic muscle gain.
  • She warns to be cautious in anyone with active cancer or a history of cancer since growth hormone is a growth signal, and flags insulin resistance and water retention as possible concerns.
  • She recommends taking it fasted since eating triggers somatostatin, which blocks the growth hormone release, and says she personally has not seen or heard of severe allergic reactions to ipamorelin, unlike what she has seen with the GHRH peptides.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

Dr. Craig Koniver

Dr. Craig Koniver does not run a channel of his own. Each video below is an interview published by the show that recorded it.

In “Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver” on Andrew Huberman, Dr. Craig Koniver discusses Ipamorelin. What he says, in short:

  • He describes ipamorelin as a growth hormone secretagogue that travels to the pituitary and prompts a release of the person's own growth hormone rather than supplying growth hormone itself.
  • He calls it the most specific for the growth hormone receptor but also the weakest, so the pulse it produces is not a big burst.
  • He contrasts it with GHRP-6, saying ipamorelin does not bring the prolactin, cortisol and appetite effects that GHRP-6 can.
  • He says the dose for it and most growth hormone releasing peptides should be 100 micrograms as a maximum to bind the receptor, and calls it clean at 100 micrograms or less.
  • He says he has seen rare cases of anaphylaxis with it and thinks that happens when people push doses of 200, 300 or 400 micrograms chasing the flushing sensation as proof it is working.
  • He says it is taken at bedtime with no carbohydrates in the preceding period, and describes stacking it with tesamorelin and BPC-157 in one bedtime shot that his clinic labeled a fat loss combination.

very clean you know as long as you stay within 100 micrograms or less people are going to lean out a little bit sleep a little bit better there's no no real side effects

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Is Peptide Therapy the Future of Medicine? | Dr. Craig Koniver” on The Ancient Health Podcast, Dr. Craig Koniver discusses Ipamorelin. What he says, in short:

  • He says his clinic moved on from earlier growth hormone releasing peptides to ones like ipamorelin as the category advanced.
  • He describes it as a fitness peptide that prompts the body to put out a little more of its own growth hormone.
  • He says he combines it with BPC-157 because BPC upregulates growth hormone receptors, so you get much more efficiency out of the pairing.
  • He suggests combining it with epitalon and pinealon for sleep, saying growth hormone has a quality that is not sedating but helps you get quality sleep.
  • He frames the sleep benefit as feeding recovery, since better sleep means waking refreshed and recovering faster.
  • He says peptides in this class are so safe that his clinic rarely ever sees any negative side effects.

if you combine them with a growth hormone releasing peptide like ipamorelin or even ghrp6 or ghrp2 again growth hormone has a really nice kind of not sedating quality but helps you get quality sleep

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

1 more video where Dr. Craig Koniver covers Ipamorelin

In “Dr. Craig Koniver: Health Optimization with Peptides, Light Therapy, and Methylene Blue” on Health Optimization Medicine Podcast, Dr. Craig Koniver discusses Ipamorelin. What he says, in short:

  • He calls ipamorelin probably the most common of the growth hormone releasing peptides his clinic uses.
  • He describes the pathway as the injected peptide travelling to the pituitary, triggering growth hormone release, which reaches the liver to make IGF-1 that then binds receptors in muscle and tissue.
  • He says some people expected growth hormone releasing peptides to raise IGF-1 on labs, and that his clinic found that not to be true.
  • He offers his own interpretation, hedged as what he thinks, that these peptides make IGF-1 more efficient rather than raising it.
  • He says he does not like using labs either to get a baseline or to judge how well it is working, and prefers to measure clinically and by how the person feels.
  • He says his clinic does not give this class intravenously, and lists his contraindications for peptides generally as people under 18, pregnant women and anyone with active cancer.

whether it be ipamorelin, which is the probably the most common, that we're going to see a rise in that IGF-1. Um we found that not to be true.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Dr. Jones, DC

In “You're Injecting Tesamorelin WRONG! Doctor Explains How to Inject Tesamorelin”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He classifies ipamorelin as a growth hormone releasing peptide, a GHRP, working through a separate pathway from the GHRH analogs.
  • He explains the split as GHRH telling the pituitary to release while GHRP tells it to release more and harder through a different door.
  • He says the smart way to amplify tesamorelin is a low dose of ipamorelin rather than a second GHRH, because adding another GHRH is like flooring the gas pedal with two feet.
  • He is candid that his clinic does not always prescribe ipamorelin alongside tesamorelin, saying they get phenomenal results with tesamorelin alone.
  • He says any stack his medical team builds starts with a conservative dose dialed to how the individual responds rather than to what a chart says they should tolerate.

that's why the smart pairing is tesamorelin with a low dose of ipamorelin

We don't even need to prescribe ipa with tesamorelin all the time.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Dr. Explains How to Correctly Stack Tesamorelin and Ipamorelin”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He describes ipamorelin as a GHRP working on a separate receptor that does two things at once, making the growth hormone pulse bigger and quieting somatostatin.
  • He frames the pairing as tesamorelin being the message that says fire while ipamorelin makes the pulse bigger and lifts the body's own brake at the same time.
  • He argues the two do not overlap, so the combination produces a bigger and more natural pulse than either alone, and calls that the reason the pairing took off.
  • He says growth hormone and insulin work against each other, so injecting after a carb-heavy meal fights the shot, and that bedtime wins for once-daily dosing with a fasted morning shot as the second slot if dosing twice a day.
  • He gives a rhythm of five or six nights on and one or two nights off, arguing that nightly stimulation without a break makes the system less responsive over time.
  • He says people should not judge it in a single week, that most notice little for the first few weeks, and that in his clinic's experience real changes tend to show up a couple months in.
  • He tells viewers to establish baseline blood work and to pull IGF-1 rather than guess, and says prolactin is checked early with fasting insulin and hemoglobin A1C worth watching.

It makes that pulse bigger, and it helps quiet somatostatin, which is your body's natural break on growth hormone release.

Five or six nights on, one or two nights off.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

9 more videos where Dr. Jones, DC covers Ipamorelin

In “Dr. Explains Why CJC/IPA is KING of Growth Hormone Peptides”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He calls ipamorelin a ghrelin mimetic that releases the brake by working through ghrelin receptors to help override somatostatin's inhibitory signal.
  • He says ipamorelin is more selective than older ghrelin mimetics and is generally better tolerated without the appetite spikes he attributes to MK-677, and that you control the timing where MK-677 is always on.
  • He states as a clinic dose ballpark 100 micrograms of CJC-1295 with upwards of 150 to 250 micrograms of ipamorelin, and says ipamorelin can go to roughly 250 or 300 micrograms before saturation while CJC saturates around 100.
  • He says to inject at least 90 to 120 minutes after the last meal, ideally before bed on an empty stomach, because elevated insulin blunts growth hormone release.
  • He says people should expect 8 to 12 weeks before sleep, recovery and body composition changes become noticeable, based on what he sees with patients and what secretagogue research suggests.
  • He reports clinically that effects start to diminish around month four or five without cycling, so his protocol uses 5 days on and 2 days off plus a longer break of a few weeks to a month after a few months.
  • He says IGF-1 monitoring matters because chronically high growth hormone and IGF-1, as in acromegaly, are linked to insulin resistance.
  • He warns that research grade does not guarantee pharmaceutical purity and tells viewers to get third-party testing or at minimum an independent certificate of analysis.

Many peptide clinics, including ours, use doses in the ballpark of, say, 100 micrograms of CJC 1295 and upwards of 150 to 250 micrograms of Ipamorelin.

you're looking at 8 to 12 weeks before changes in sleep, recovery, and body composition become noticeable

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Explains Why CJC/Ipamorelin Are the BEST Muscle Building & Fat Loss Peptides”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He says ipamorelin works on the ghrelin pathway and that its main job is not to push but to get out of the way by easing off the body's braking system on growth hormone release.
  • He is explicit that the job his clinic hires the pairing for is muscle preservation, protecting what is already built during calorie deficits and aggressive fasting, not muscle building.
  • He says that in his clinical experience the protocol runs 8 to 12 weeks before most people notice a change they describe out loud, with sleep improvements usually showing up first.
  • He calls mixing and concentration error the single biggest reason people get nothing, saying two people with identical vials can be off by a multiple of two, three or sometimes ten.
  • He describes mild short-lived puffiness early in a protocol as a known effect of working on this axis, while telling viewers that swelling which is new, worsening or thickening goes to the prescriber.
  • He warns that sustained stimulation of this system can push fasting glucose up and nudge insulin sensitivity the wrong way, the same mechanism he cites in the MK-677 data, which is why he says running it indefinitely is not the default.
  • He says IGF-1 reflects baseline exposure rather than individual bursts, so a number that barely moved can lead someone to quit a protocol that was working, and he notes it is not a routine lab and his medical team uses it selectively.

In our clinical experience, this protocol runs 8 to 12 weeks before most people will notice a change that they describe out loud.

the job that we hire them for is preservation

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The Best Peptide Stack For Lean Muscle Growth for 2026”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He calls CJC-1295 with ipamorelin the cornerstone of the lean muscle stack he uses in his clinic, with ipamorelin working on a different receptor to enhance the release.
  • He says the theory behind the combination is that stimulating both pathways gives more acceleration than either alone, and that this is what he sees clinically in patients.
  • He stresses that the approach works with the body's natural pulsatile rhythm rather than overriding it.
  • He says that based on what he sees in practice this combination tends to have a cleaner profile, with patients generally not reporting the cortisol spikes or appetite changes seen with other growth hormone secreting peptides.
  • He lists observed benefits in his patients as better fat mobilization, support for muscle protein synthesis, faster recovery, improved sleep and sometimes skin and joint changes, while saying results vary person to person.
  • He hedges the fountain of youth framing by saying the evidence is stronger in the body composition and recovery category.

Our patients generally don't report the cortisol spikes or the appetite changes that you sometimes see with other growth hormone secreting peptides.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “The BEST Peptide Stack for Building Muscle (CJC-1295 + Ipamorelin)”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He calls CJC-1295 with ipamorelin the best value in the growth hormone category rather than the most proven for one job, and says in the same breath that it will not build a single pound of muscle on its own.
  • He describes ipamorelin as turning down the body's built-in shutoff signal so the pulse comes out bigger than either compound could trigger alone.
  • He says the biggest execution error is eating close to the shot, because the insulin response slams the brakes on growth hormone, and he tells viewers to inject before bed a couple hours after the last meal.
  • He says transdermal creams and nasal sprays of this stack do not reliably deliver the dose and that injection is the route that works.
  • He warns against chasing a bigger dose, saying that past a certain point you are only saturating receptors, so the right dose timed right beats a big dose timed wrong.
  • He gives a cycling structure of 5 days on and 2 days off weekly plus about a month off every 4 to 6 months, and he is upfront that the exact reset protocol is not proven down to the science and is how he would run it himself.
  • He says gray market vials come back underdosed, mislabeled or nearly empty in independent testing, so a perfect protocol on a fake product returns a perfect zero, and he points to 503A compounding pharmacies instead.

It's earned the word best, and it will not build you a single pound of muscle on its own.

Now, is the exact reset protocol proven down to the exact science? No, but this is the necessary cautious way to run it, and it's how I'd run it myself.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Use This Peptide Stack To Lose Weight FAST Before Summer (Doctor Explains)”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He places CJC-1295 with ipamorelin in the third phase of his stack, which he calls the acceleration and preservation phase, and describes it as the muscle preservation layer rather than a fat loss tool.
  • He describes ipamorelin as removing the brakes while CJC-1295 acts as the gas pedal on the pituitary, together supporting fat mobilization, muscle building and recovery.
  • He says the compound depends on sleep because the biggest growth hormone bursts happen in deep sleep, so five hours a night leaves most of its benefit on the table.
  • He says patients spending hundreds or thousands on growth hormone peptides while averaging five hours of sleep are flushing the investment, which he presents as a pattern he sees weekly in clinic.
  • He says the pairing cannot protect muscle without raw material and sets a protein target of at least 1 gram per pound of ideal body weight rather than current weight.
  • He tells patients running CJC-1295 to monitor IGF-1 through blood tests, warning that IGF-1 staying high for a long time without monitoring can work against metabolic goals.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours.

In “The ULTIMATE Peptide Stack For Fat Loss & Metabolic Flexibility! | Dr. Jones DC”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He states as his clinic protocol 200 micrograms of ipamorelin with 100 micrograms of CJC-1295, run 5 days on and 2 days off, with AM and PM dosing both possible.
  • He calls the combination very potent and says that if you can still get it, it is definitely better than sermorelin, while adding that sermorelin would work as well.
  • He notes that access to CJC-1295 with ipamorelin has been getting harder because it has recently been on what he calls the FDA's banned list.
  • He groups it with the growth hormone secretagogues whose job is stimulating release of your own growth hormone, on the reasoning that growth hormone levels decrease with age.
  • He says his medical practitioners do not prescribe regular growth hormone because they have seen too many issues with chronic use and better results from stimulating endogenous release.
  • He still ranks AOD-9604 above the growth hormone secretagogues for the specific goal of metabolic flexibility on a GLP-1.

200 micrograms of the Ipamorelin and 100 micrograms of the CJC-1295. 5 days on, 2 days off.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The Best Peptide Stack For Massive Muscle Growth in 2026”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He calls CJC-1295 with ipamorelin the cornerstone of his muscle building stack and his personal favorite growth hormone secretagogue.
  • He describes ipamorelin as a GHRP that releases the brake, removing the inhibition holding back growth hormone release, while CJC-1295 presses the gas.
  • He says what is specifically good about ipamorelin is that it boosts growth hormone while avoiding spikes in cortisol, prolactin and excessive hunger, which is why he prefers it over hexarelin, GHRP-2 and GHRP-6.
  • He frames the mechanism as optimizing frequency and amplitude of natural pulses so the growth hormone to IGF-1 pathway gets through, since he says growth hormone does not build muscle directly.
  • He says his clinic will not touch IGF-1 LR3, follistatin or MK-677 because they bypass natural pathways and the human data is minimal relative to the risks.

it boosts growth hormone, but it avoids spiking cortisol, prolactin, excessive amounts of hunger.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The 10 Most POWERFUL Peptide Stacks (Science Backed Peptides)”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He says ipamorelin stimulates the actual growth hormone release without increasing prolactin or cortisol the way older growth hormone peptides such as the hexarelins did.
  • He states as a typical protocol around 100 to 150 micrograms of CJC-1295 combined with 100 to 250 micrograms of ipamorelin, injected twice daily in the morning and in the evening before bed.
  • He adds the handling rules of not eating before or after the shot, running 5 days on and 2 days off, and giving it 3 to 6 months before taking a break.
  • He says the theory is that the two together create a pulsatile growth hormone pattern closer to the body's own, and reports that in his clinical experience patients prescribed the combination see consistent body composition improvements when it is paired with proper training.
  • He offers a clinic anecdote of a 43-year-old patient who lost 35 pounds of which a DEXA scan showed 15 pounds was muscle, and who regained 8 pounds of muscle while losing another 10 pounds of fat over six months with growth hormone optimization, resistance training and higher protein.
  • He says dosing varies by goal, with lower ranges for anti-aging and higher for body recomposition, and tells viewers to work with a physician on it.

The protocol typically is around 100 to maybe 150 micrograms of CJC 1295 combined with anywhere between 100 to 200 maybe 250 micrograms of hypomearin ideally injected twice daily in the morning and in the evening before bed.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “If I Started Peptides Today, I’d Do This (Doctor’s Ultimate Peptide Roadmap)”, Dr. Jones, DC discusses Ipamorelin. What he says, in short:

  • He pushes back directly on the forum idea that ipamorelin is the fat loss peptide, saying that is what the forums say rather than what he sees.
  • He calls growth hormone support a slow burn optimization layer and says starting there when stubborn fat is the main problem is like remodeling the kitchen while the house is on fire.
  • He places CJC-1295 with ipamorelin in the sleep, recovery and longevity door of his roadmap rather than the fat loss door.
  • He says the layer usually works best after the foundation is set, because growth hormone release happens in deep sleep and supporting the pathway while sleep is a mess amplifies a whisper.
  • He allows that his medical team sometimes starts a patient here on day one when sleep is the presenting problem, and says sleep quality is usually the first thing to move and is measurable within weeks.

Growth hormone support is a slow burn optimization layer.

Wait, I thought Ipamorelin was the fat loss peptide.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Common questions

Does ipamorelin actually work for anything in humans?

There is only one published human trial, and it tested ipamorelin for speeding up bowel recovery after abdominal surgery. It found no statistically significant benefit over placebo. A larger follow up trial of 320 people was run afterward and has never been published or had results posted anywhere. No human trial has ever tested ipamorelin for the reasons most people buy it today, including muscle gain, fat loss, better sleep, or anti-aging.

Is ipamorelin approved by the FDA?

No. There is no approved ipamorelin drug product of any kind. FDA places ipamorelin acetate in Category 2 of its bulk drug substance review, its category for substances that may present significant safety risks, which means it cannot lawfully be used in compounded drugs under sections 503A or 503B of federal law.

What is ipamorelin supposed to do in the body?

It binds the ghrelin receptor and prompts the pituitary gland to release a pulse of growth hormone. Early animal and lab work found this happens without raising cortisol or ACTH the way some related compounds do, which is where its reputation for being a cleaner or more selective growth hormone releaser comes from. That selectivity has only been shown in cells and animals, not confirmed as a clinical advantage in any human trial.

Is ipamorelin safe?

There is no large or long term human safety record. The one published human trial found a similar or slightly lower rate of side effects with ipamorelin than with placebo, and no deaths in its abstract. But FDA's own compounding safety review cites that same trial as reporting a death among the serious adverse events, a detail that does not appear in the published abstract and could not be independently confirmed here. Either way, the human evidence base is far too small, two studies and about 154 people total, to call the drug safe or unsafe with any confidence.

How is ipamorelin different from other growth hormone secretagogues like GHRP-2, GHRP-6, or ibutamoren (MK-677)?

In animal and cell studies, ipamorelin released growth hormone about as strongly as GHRP-6 but without raising cortisol or ACTH, while GHRP-6 and GHRP-2 both raised those hormones. That is a lab finding about hormone selectivity, not a comparison of clinical benefit or human safety, since none of these compounds has a solid human trial record either.

Who ran the research on ipamorelin?

Novo Nordisk developed the compound and published the original animal and cell pharmacology in the 1990s. Helsinn Therapeutics and Helsinn Healthcare later ran the human trials and the follow up animal studies testing it for postoperative ileus. No independent, non industry funded human trial of ipamorelin has been published.

What would change the picture?

Publication of the 320 person confirmatory trial that finished in 2014 and has never been released would be the single biggest change, since it is the largest human dataset that exists and nobody outside the company has seen it. Beyond that, there simply are no human trials testing the muscle, fat loss, sleep, or anti-aging uses ipamorelin is actually sold for, so any of those would also change what is currently an almost entirely animal based evidence picture.

Sources

  1. Adeghate (2004). PMID 15665799
  2. Andersen (2001). PMID 11735244
  3. Beck (2014). PMID 25331030
  4. Coutinho (2026). PMID 41880199
  5. Gobburu (1999). PMID 10496658
  6. Greenwood-Van Meerveld (2012). PMID 27186127
  7. Lall (2001). PMID 11162489
  8. Mendias (2026). PMID 41966639
  9. Raun (1998). PMID 9849822
  10. Svensson (2000). PMID 10828840
  11. Venkova (2009). PMID 19289567

Ipamorelin acetate is Category 2 under FDA's 503B interim policy for bulk drug substances that may present significant safety risks, based on an evaluation current as of 04/22/2026. It does not appear on either the 503A or 503B lists of substances that may be used in compounding. Checked 08-26-2026.

Want these studies next to every other one on the site?

Open the evidence table

Mixing a vial? Do the math with the calculator.

Open the calculator